Table 1. Characteristics and Details of Antihypertensive Drugs of Patients in Each Study Year.

From: Cross-sectional Survey of Hypertension Management among Patients Stratified by Chronic Kidney Disease in Japan

Study year 2011 2014 2021 P-value
a. Patients in CKD(+) group
Number of cases 316 152 396
Sex (women) 156 (49%) 57 (38%)* 165 (42%) 0.03
Age (years-old) 73.4 ± 10.7 71.7 ± 12.5 72.9 ± 10.2 0.26
BW (kg) 60.7 ± 12.3 61.6 ± 11.8 65.8 ± 13.0*† <0.001§
BMI 24.4 ± 3.6 24.2 ± 4.7 25.3 ± 3.6*† 0.002
History of hypertension (years) 9.2 ± 7.3 no data 13.7 ± 8.5 <0.001
(n = 286) (n = 237)
Current smoker 59 (25%) 34 (33%) 43 (11%) <0.001
(n = 241) (n = 102) (n = 396)*†
Current drinker 93 (41%) 36 (44%) 168 (43%) 0.86
(n = 227) (n = 82) (n = 392)
DM 64 (20%)†‡ 52 (34%)*‡ 292 (74%)*† <0.001
IHD 9 (3%)†‡ 24 (16%)* 57 (15%) <0.001
(n = 389)*
CVD 23 (7%) 15 (10%) 36 (9%) 0.53
(n = 385)
eGFR(mL/min/1.73 m2) 58.6 ± 18.7 no data 54.8 ± 17.0 0.004
(n = 313) (n = 395)
Presence of proteinuria or albuminuria 157 (52%) 112 (74%) 135 (37%) 0.001
(n = 302)†‡ (n = 152)*‡ (n = 369)*†
Estimated Salt intake (g/day) no data no data 8.9 ± 2.0
(n = 108)
Presence of the guidance of salt restriction diet 261 (83%) no data 269 (76%) 0.04
Numbers of antihypertensive drugs 2.0 ± 1.0†‡ 2.3 ± 1.0*‡ 1.8 ± 0.9*† <0.001
The prescription of antihypertensive drugs
CCB 233 (74%) 124 (82%) 284 (72%) 0.06
ARB 241 (76%) 121 (80%) 258 (65%)*† <0.001
ACEi 10 (3%) 8 (4%) 18 (5%) 0.64
MRB 17 (5%) 12 (8%) 36 (9%) 0.17
β-blocker 47 (15%) 28 (18%) 50 (13%) 0.22
α-blocker 28 (9%) 19 (13%) 13 (3%)*† <0.001
Diuretics 44 (14%) 38 (25%)*‡ 39 (10%) <0.001
Thiazide 42 (13%) 28 (18%) no data 0.15
Loop 2 (1%) 10 (7%) no data <0.001
b. Patients in CKD (-) group
Number of cases 488 946 385
Sex (women) 251(51%) 506 (54%) 176 (46%) 0.04
Age (years-old) 66.8 ± 10.9 68.0 ± 12.3 66.7 ± 10.7 0.08
BW (kg) 61.8 ± 13.5 61.4 ± 12.5 65.6 ± 13.0*† <0.0001
BMI 24.6 ± 4.1 24.6 ± 5.5 24.9 ± 3.8 0.64
History of hypertension (years) 7.3 ± 5.9 no data 10.3 ± 5.8 <0.001
(n = 430) (n = 226)
Current smoker 102 (26%) 152 (21%) 39 (10%) <0.001
(n = 392) (n = 730) (n = 380)*†
Current drinker 186 (51%) 290 (45%) 200 (52%) 0.04
(n = 366) (n = 646) (n = 382)
DM 85 (17%) 146 (15%) 306 (54%)*† <0.001
IHD 7 (1%)†‡ 44 (5%)* 24 (6%) <0.001
(n = 375)*
CVD 15 (3%) 33 (4%) 14 (4%) 0.85
(n = 371)
eGFR (mL/min/1.73m2) 80.3 ± 19.0 no data 75.4 ± 11.3 <0.001
(n = 488) (n = 385)
Presence of proteinuria or albuminuria 0 0 0
Estimated salt intake (g/day) no data no data 9.5 ± 2.1
(n = 91)
Presence of the guidance of salt restriction diet 392 (80%) no data 265 (74%) 0.04
Numbers of antihypertensive drugs 1.9 ± 0.9 2.0 ± 0.9 1.6 ± 0.8*† <0.001
The prescription of antihypertensive drugs
CCB 390 (80%) 713 (75%) 250 (65%)*† <0.001
ARB 360 (74%) 742 (78%) 261 (68%) <0.001
ACEi 27 (6%) 38 (4%) 8 (2%)* 0.04
MRB 13 (3%)†‡ 69 (7%)* 24 (6%)* 0.002
β-blocker 55 (11%) 87 (9%) 37 (10%) 0.45
α-blocker 37 (8%) 76 (8%) 11 (3%)*† 0.002
Diuretics 56 (12%) 116 (12%)*‡ 21 (6%) <0.001
Thiazide 52 (11%) 113 (12%) no data 0.47
Loop 4 (1%) 3 (0.3%) no data 0.20
Table 2. Office and Home BP Values Stratified by Target BP Values in Each Study Year.

From: Cross-sectional Survey of Hypertension Management among Patients Stratified by Chronic Kidney Disease in Japan

Study year 2011 2014 2021 p Value by ANOVA Post-hoc analysis by Bonferroni correction
Unadjusted data
CKD (+) Number of cases 316 152 396
Number of cases who measured home-BP 178 145 204
Office-BP SBP 132.9 ± 13.4 135.6 ± 17.3 134.9 ± 17.1 0.14
DBP 74.6 ± 9.6 75.4 ± 12.2 74.8 ± 11.5 0.74
Home-BP SBP 129.8 ± 12.3 132.2 ± 11.8 127.6 ± 8.0 <0.001 2014 vs. 2021, p < 0.001
DBP 75.1 ± 9.3 75.8 ± 10.5 75.0 ± 8.4 0.68
CKD (−) Number of cases 488 946 385
Number of cases who measured home-BP 268 896 269
Office-BP SBP 133.2 ± 12.8 132.7 ± 14.0 138.0 ± 17.4 <0.001 2011 vs. 2021, p < 0.001,
2014 vs 2021, p < 0.001
DBP 76.7 ± 9.0 77.5 ± 10.4 78.9 ± 11.1 0.006 2011 vs. 2021, p = 0.005
Home-BP SBP 127.7 ± 9.6 129.0 ± 9.9 128.7 ± 9.5 0.14
DBP 75.8 ± 8.3 76.3 ± 8.6 77.7 ± 7.9 0.02 2011 vs. 2021, p = 0.02,
2014 vs. 2021, p = 0.04
Adjusted with age, sex, BMI, the existence of DM, current smoker, and current drinker
CKD (+) Office-BP SBP 133.96 ± 1.07 133.68 ± 1.21 133.91 ± 0.81 0.07
DBP 75.53 ± 3.26 75.21 ± 3.97 74.76 ± 3.72 0.04 2011 vs. 2021, p = 0.03
Home-BP SBP 129.19 ± 1.89 129.42 ± 1.74 128.61 ± 1.30 <0.001 2011 vs. 2021, p < 0.001,
2014 vs. 2021, p < 0.001
DBP 74.72 ± 3.05 74.61 ± 3.76 74.01 ± 3.33 0.03 2011 vs. 2021, p = 0.03
CKD (−) Office-BP SBP 133.85 ± 1.07 134.00 ± 0.98 133.94 ± 0.81 0.06
DBP 77.79 ± 3.62 77.51 ± 4.26 77.31 ± 4.00 0.26
Home-BP SBP 128.88 ± 1.78 128.76 ± 1.68 128.36 ± 1.30 <0.001 2011 vs. 2021, p < 0.001,
2014 vs. 2021, p < 0.001
DBP 76.74 ± 3.37 76.37 ± 3.74 76.16 ± 3.54 0.08
PAGE TOP